Galapagos meets primary goal in phase 3 study for rare autoimmune disease asset
Source: SeekingAlpha
2025-12-18 20:07:02 ET
More on Galapagos
- Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
- Galapagos NV 2025 Q3 - Results - Earnings Call Presentation
- Galapagos falls after plans to shut down cell therapy unit
- Galapagos updates on strategic alternatives for cell therapy business
- Seeking Alpha’s Quant Rating on Galapagos
Read the full article on Seeking Alpha
For further details see:
Galapagos meets primary goal in phase 3 study for rare autoimmune disease asset
Galapagos NV
NASDAQ: GLPG
GLPG Trading
-1.11% G/L:
$32.15 Last:
19,545 Volume:
$32.12 Open:
GLPG Latest News
GLPG Stock Data
$2,234,899,163
48,533,193
0.1%
30
N/A
Biotechnology & Life Sciences
Healthcare
BE
Mechelen
